Fed. Circ. Rules Enbrel Doesn't Infringe Ariad Patent
A federal appeals court has ruled that Amgen Inc.'s arthritis drug Enbrel does not infringe an Ariad Pharmaceuticals Inc. patent, affirming an order by a district court....To view the full article, register now.
Already a subscriber? Click here to view full article